MUMBAI (Reuters) - Indian drugmaker Lupin plans to launch at
least 15 new generic products in the
United States in the current
fiscal year ending March 2013, as it looks to push up sales in the
world's biggest drug market, a top executive said on Tuesday.
"About eight to 10 (from the 15), I would say, will be oral contraceptives," Vinita Gupta, chief executive of Lupin's U.S. unit, told Reuters.
Lupin has launched five products in the U.S. this fiscal year.
The drugmaker had said earlier its September quarter net profit rose 9 percent to 2.91 billion rupees to beat analyst estimates.
"About eight to 10 (from the 15), I would say, will be oral contraceptives," Vinita Gupta, chief executive of Lupin's U.S. unit, told Reuters.
Lupin has launched five products in the U.S. this fiscal year.
The drugmaker had said earlier its September quarter net profit rose 9 percent to 2.91 billion rupees to beat analyst estimates.
0 comments:
Post a Comment
Let Us Know Your Opinion!